Meggendorfer, Manja

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 196

Genomic subtyping and therapeutic targeting of acute erythroleukemia

Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J. K., Shi, L., Pounds, S. B., Carmichael, C. L., Masih, K. E., Morris, S. M., Lindsley, R. C., et al. (2019) · Nature Genetics

Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

Cited by 155

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 53

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

Bahaj, W., Kewan, T., Gurnari, C., Durmaz, A., Ponvilawan, B., Pandit, I., Kubota, Y., Ogbue, O. D., Zawit, M., Madanat, Y., et al. (2023) · Journal of Hematology & Oncology

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 45

Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke

Mayerhofer, E., Strecker, C., Becker, H., Georgakis, M. K., Uddin, M. M., Hoffmann, M. M., Nadarajah, N., Meggendorfer, M., Haferlach, T., Rosand, J., et al. (2023) · Stroke

Acute Myeloid Leukemia ResearchAcute Ischemic Stroke Management

Cited by 41